Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurological Disorder, Oncology & Rare Disease Development.
TarMart Solution Ecosystem & Related Targets
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ATP1A3 Full-Length Membrane Protein HEK293 expressed, native glycosylation, sequence verified, high purity (>90% by SDS-PAGE). Detergent-solubilized or nanodisc-reconstituted options. |
View ATP1A3 Products |
| Gene Delivery | ATP1A3 Lentivirus Premade Particles Full-length ORF, endotoxin controlled (<0.01 EU/μL). Ideal for stable cell line construction and functional pump assays. |
View ATP1A3 Products |
| Benchmark Ab | Anti-ATP1A3 (Pan-alpha3 Specific) Recombinant monoclonal, sequence verified. Isoform-selective (minimal cross-reactivity to ATP1A1/ATP1A2). |
View ATP1A3 Products |
| Validator | ATP1A3 siRNA Set (3 unique sequences) For knockdown verification and specificity controls. Sequence verified, HPLC purified. |
View ATP1A3 Products |
| Isoform Control A | ATP1A1 (Alpha-1 Subunit) Cardiac/ubiquitous isoform; essential for cardiac toxicity counter-screen. |
View ATP1A1 Products |
| Isoform Control B | ATP1A2 (Alpha-2 Subunit) Glial/muscle isoform; CNS off-target liability panel. |
View ATP1A2 Products |
| Signaling Partner | SRC (Tyrosine Kinase) Direct interactor with Na+/K+-ATPase signalosome; for mechanism studies. |
View SRC Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (ATP1A1/ATP1A2/ATP1A3 share >85% identity) | Full-length Isoform Panel (Human ATP1A1, ATP1A2, ATP1A3) expressed in HEK293. Sequence Verified by Mass Spectrometry. Enables orthogonal selectivity screening. |
| Native Conformation, Glycosylation & Pump State Specificity | HEK293 stable cell lines preserving native glycosylation and 10-TM membrane topology. Supports functional thapsigargin/ouabain challenge assays for E1/E2 conformational analysis. |
| Lack of Pharmacological Controls / False Positives | Benchmark reference antibody (biosimilar sequence) and validated siRNA set included for genetic specificity confirmation (RNAi rescue experiments). |
| Mutant Variant Screening (AHC/RDP models) | Disease-mutation ORF clones (e.g., D801N, E815K, G947R) available as custom lentivirus; sequence verified, high purity. |
| CNS Penetration Mimicry | High-concentration stability proteins (>2 mg/mL) for Biacore/SPR under physiological ionic conditions. |
Live ATP1A3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic focus on ATP1A3 is bifurcating into two distinct innovation vectors: rare neurological disorders and oncology. In rare neurological diseases such as Alternating Hemiplegia of Childhood (AHC), Rapid-onset Dystonia-Parkinsonism (RDP), and CAPOS syndrome, the emphasis is on small-molecule activators, antisense oligonucleotides, and gene-modulation strategies to correct haploinsufficiency or mutant protein folding defects. Concurrently, in oncology, ATP1A3 is emerging as a potential target in glioblastoma and neuroblastoma, where isoform-selective cardiac glycoside analogs are being explored to circumvent ATP1A1-mediated cardiotoxicity. The next wave of R&D is targeting allosteric modulators that discriminate between alpha-isoform extracellular conformations, with blood-brain barrier penetration being a critical challenge for CNS indications. As first-generation therapies advance through preclinical and early clinical stages, the pipeline is increasingly dominated by precision genetic medicines and highly specific small molecule modulators.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Isoform-Selective Inhibitor) | Emerging biotechs & academic consortia (e.g., Tocris Bioscience) | Glioblastoma, Neuroblastoma | Isoform panel cell lines (ATP1A1/2/3) for selectivity index determination via Rb+ flux |
| Small Molecule (Activator / Stabilizer) | Rare disease focused biotech | AHC, RDP, CAPOS syndrome | Mutant vs WT stable cell lines for compound rescue assays (survival, ion flux) |
| Antisense Oligonucleotides (ASO) | Ionis Pharmaceuticals, Roche | Haploinsufficiency disorders | Allele-specific knockdown evaluation; need WT and mutant ORF templates |
| Gene Therapy (AAV) | Biogen, Novartis, Orphan drug developers | Severe neurological (AHC, genetic dystonias) | High-titer lentivirus for in vitro transduction efficiency and expression validation |
| Monoclonal Antibodies | Academic research groups | Glioblastoma stem cell targeting | Cell-surface binding and internalization assays using intact membrane systems; knockdown validation with siRNA |